Kirby John J. 4
4 · Verrica Pharmaceuticals Inc. · Filed Nov 25, 2025
Insider Transaction Report
Form 4
Kirby John J.
Interim CFO
Transactions
- Purchase
Common Stock
2025-11-25$4.24/sh+3,536$15,001→ 8,962 total - Purchase
Series C Warrant (right to buy)
2025-11-25+884→ 884 totalExercise: $6.32Exp: 2030-11-25→ Common Stock (884 underlying)
Footnotes (3)
- [F1]Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
- [F2]Immediately exercisable.
- [F3]The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.